Sanofi joins in vivo cell engineering wave, snapping up stealthy Fred Hutch mRNA delivery spinout 

Acquired by Sanofi before making its official debut, Tidal is the latest example of a vector-focused company enabling democratization of immune cell therapies via in vivo engineering. 

Shareholders of the Fred Hutchinson Cancer Research Center spinout, which was seeded by Mission BioCapital and based at the Lab Central accelerator in Cambridge, Mass., will receive $160 million up front and up to $310 million in milestone payments from Sanofi (Euronext:SAN; NASDAQ:SNY). ...